Karyopharm Therapeutics Inc. (KPTI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol KPTI
- Company Karyopharm Therapeutics Inc.
- Price $0.87
- Changes Percentage 4
- Change 0.0333
- Day Low $0.78
- Day High $0.99
- Year High $10.99
- Year Low $1.24
- Market Cap $39,206,891
- Price Avg 50 EMA (D) $3.29
- Price Avg 200 EMA (D) $6.9
- Exchange NASDAQ
- Volume 668,355
- Average Volume 1,592,431
- Open $0.81
- Previous Close $0.83
- EPS -13.06
- PE -0.13
- Earnings Announcement 2026-11-02 05:00:00
- Shares Outstanding $22,662,943
Company brief: KARYOPHARM THERAPEUTICS INC. (KPTI )
- Healthcare
- Biotechnology
- Mr. Richard A. Paulson M.B.A.
- https://www.karyopharm.com
- US
- N/A
- 11-06-2013
- US48576U1060
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.